Mitsui Chemicals Group to exhibit at ProPak Asia 2025
SINGAPORE--(BUSINESS WIRE)--Mitsui Chemicals Group will exhibit at the ProPak Asia 2025 from 11 to 14 June 2025, at Bangkok International Trade & Exhibition Centre (BITEC) in Thailand.
New prototypes will be on display for booth visitors to experience the different application structures using our products.
Share
With the growing focus on sustainability in packaging solutions, Mitsui Chemicals Group will present close to 10 products that can be applied to various sustainable packaging requirements. In addition, new prototypes will be on display for booth visitors to experience the different application structures using our products.
Exhibition details:
Prototypes on display:
Recycle-ready polypropylene-based pouch
Maximized single polymer material.
High barrier sealable BOPP film to reduce overall virgin plastic use.
Recycle-ready polyolefin-based pouch
Suitable for acidic product packaging.
Special EVOLUE™ grade to allow seal through contamination.
TAKELAC™/TAKENATE™ combination to retain adhesion under aggressive environment.
Dead fold film
Polyethylene-based film modified using Mitsui Chemicals product.
Retain folding property after removal of pressure.
Suitable for diverse industries' applications.
Printable PCR film
Mechanical PCR (Re'PRM™) based mono-layer film with low gel content for film surface printing.
Suitable for regular FMCG products' secondary packaging.
Mono-polyethylene pouch with PCR content
Combining Re'PRM™ resin with EVOLUE™ high-performance polyethylene resin.
Offers enhanced sealability and improved pouch appearance, thus achieving a balance of sustainability and premium packaging aesthetics.
Expand
About Mitsui Chemicals Group
Mitsui Chemicals Inc. (MCI) is one of the largest chemical companies in Japan. Our innovative technologies and materials, along with products that offer new functionality, are being used for a wide range of fields such as automotive, ICT, healthcare, environment and energy, and packaging in our society.
The group has more than 20 affiliates in Asia Pacific, providing services and solutions to various industries in the region.
About Mitsui Chemicals Asia Pacific
Established on December 1997, MCAP is the Asia Pacific Regional Headquarter of MCI, covering ASEAN, South Asia, Nations along the Gulf in Middle East, and Oceania. Being the Asia Pacific Regional Headquarter, MCAP strives to drive business growth, provide robust functional services to regional affiliates or businesses, and deliver values to customers by leveraging on the strengths of all affiliates in Mitsui Chemicals Group.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 days ago
- Business Wire
Mitsui Chemicals Group to exhibit at ProPak Asia 2025
SINGAPORE--(BUSINESS WIRE)--Mitsui Chemicals Group will exhibit at the ProPak Asia 2025 from 11 to 14 June 2025, at Bangkok International Trade & Exhibition Centre (BITEC) in Thailand. New prototypes will be on display for booth visitors to experience the different application structures using our products. Share With the growing focus on sustainability in packaging solutions, Mitsui Chemicals Group will present close to 10 products that can be applied to various sustainable packaging requirements. In addition, new prototypes will be on display for booth visitors to experience the different application structures using our products. Exhibition details: Prototypes on display: Recycle-ready polypropylene-based pouch Maximized single polymer material. High barrier sealable BOPP film to reduce overall virgin plastic use. Recycle-ready polyolefin-based pouch Suitable for acidic product packaging. Special EVOLUE™ grade to allow seal through contamination. TAKELAC™/TAKENATE™ combination to retain adhesion under aggressive environment. Dead fold film Polyethylene-based film modified using Mitsui Chemicals product. Retain folding property after removal of pressure. Suitable for diverse industries' applications. Printable PCR film Mechanical PCR (Re'PRM™) based mono-layer film with low gel content for film surface printing. Suitable for regular FMCG products' secondary packaging. Mono-polyethylene pouch with PCR content Combining Re'PRM™ resin with EVOLUE™ high-performance polyethylene resin. Offers enhanced sealability and improved pouch appearance, thus achieving a balance of sustainability and premium packaging aesthetics. Expand About Mitsui Chemicals Group Mitsui Chemicals Inc. (MCI) is one of the largest chemical companies in Japan. Our innovative technologies and materials, along with products that offer new functionality, are being used for a wide range of fields such as automotive, ICT, healthcare, environment and energy, and packaging in our society. The group has more than 20 affiliates in Asia Pacific, providing services and solutions to various industries in the region. About Mitsui Chemicals Asia Pacific Established on December 1997, MCAP is the Asia Pacific Regional Headquarter of MCI, covering ASEAN, South Asia, Nations along the Gulf in Middle East, and Oceania. Being the Asia Pacific Regional Headquarter, MCAP strives to drive business growth, provide robust functional services to regional affiliates or businesses, and deliver values to customers by leveraging on the strengths of all affiliates in Mitsui Chemicals Group.
Yahoo
3 days ago
- Yahoo
Mitsui Chemicals Group to exhibit at ProPak Asia 2025
SINGAPORE, June 04, 2025--(BUSINESS WIRE)--Mitsui Chemicals Group will exhibit at the ProPak Asia 2025 from 11 to 14 June 2025, at Bangkok International Trade & Exhibition Centre (BITEC) in Thailand. With the growing focus on sustainability in packaging solutions, Mitsui Chemicals Group will present close to 10 products that can be applied to various sustainable packaging requirements. In addition, new prototypes will be on display for booth visitors to experience the different application structures using our products. Exhibition details: Date 11 to 14 June 2025 Venue BITEC, Thailand Booth Hall 99, T65 Prototypes on display: Recycle-ready polypropylene-based pouch Maximized single polymer material. High barrier sealable BOPP film to reduce overall virgin plastic use. Recycle-ready polyolefin-based pouch Suitable for acidic product packaging. Special EVOLUE™ grade to allow seal through contamination. TAKELAC™/TAKENATE™ combination to retain adhesion under aggressive environment. Dead fold film Polyethylene-based film modified using Mitsui Chemicals product. Retain folding property after removal of pressure. Suitable for diverse industries' applications. Printable PCR film Mechanical PCR (Re'PRM™) based mono-layer film with low gel content for film surface printing. Suitable for regular FMCG products' secondary packaging. Mono-polyethylene pouch with PCR content Combining Re'PRM™ resin with EVOLUE™ high-performance polyethylene resin. Offers enhanced sealability and improved pouch appearance, thus achieving a balance of sustainability and premium packaging aesthetics. About Mitsui Chemicals Group Mitsui Chemicals Inc. (MCI) is one of the largest chemical companies in Japan. Our innovative technologies and materials, along with products that offer new functionality, are being used for a wide range of fields such as automotive, ICT, healthcare, environment and energy, and packaging in our society. The group has more than 20 affiliates in Asia Pacific, providing services and solutions to various industries in the region. About Mitsui Chemicals Asia Pacific Established on December 1997, MCAP is the Asia Pacific Regional Headquarter of MCI, covering ASEAN, South Asia, Nations along the Gulf in Middle East, and Oceania. Being the Asia Pacific Regional Headquarter, MCAP strives to drive business growth, provide robust functional services to regional affiliates or businesses, and deliver values to customers by leveraging on the strengths of all affiliates in Mitsui Chemicals Group. View source version on Contacts For enquiries about this release, please contact:Eric LimCorporate & Marketing CommunicationMitsui Chemicals Asia Pacific, Sign in to access your portfolio
Yahoo
21-05-2025
- Yahoo
Neurogen Biomarking Announces Partnership with Aranscia
Aranscia Diagnostic Laboratory and Technology Solutions Support Neurogen's Innovative Platform for the Early Detection of Mild Cognitive Impairment (MCI) and Alzheimer's Dementia CHICAGO and HOUSTON, May 21, 2025 /PRNewswire/ -- Neurogen Biomarking, the world's first ecosystem for memory loss with end-to-end patient support, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership in which Aranscia's technical and laboratory resources will help to deliver clinical insights and HIPAA-compliant connectivity for the Neurogen Biomarking ecosystem. Under this partnership, AccessDx Laboratory, an Aranscia company, will provide Neurogen with technical, operational, and analytical support resources for its blood-based biomarker test that measures phosphorylated tau (p-tau) 217, a specific marker for Alzheimer's disease pathology. AccessDx Laboratory is a CAP-accredited, CLIA-certified, NYSDOH-approved diagnostic laboratory focused on both the development and scaling of novel diagnostic programs. In addition, 2bPrecise, another Aranscia company, will provide Neurogen with software-based, EMR-agnostic clinical workflow utilities that help to securely integrate Neurogen's diagnostic results and programmatic insights across the Neurogen ecosystem and within a wide range of clinical care settings. 2bPrecise's HIPAA-compliant software solutions currently support thousands of discrete client groups, including leading health systems, municipalities, ACOs, and multi-provider organizations. "Neurogen's driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a scientifically and clinically controlled ecosystem while also guiding them every step of the way in their brain health journey," said Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking. "Aranscia's proven experience in supporting a wide range of complex diagnostic and clinical workflows, combined with their expertise in enabling innovative and secure end-to-end personalized diagnostic programs, makes them the ideal partner to help us both achieve our objectives and position for scale." Neurogen's platform is the first patient-initiated system designed to shift the paradigm of early detection of Alzheimer's disease (AD) through improved access to innovative blood biomarker testing and AI-enhanced digital and cognitive assessments. Board-certified neurologists will support eligible Neurogen patients every step of the way via telehealth, providing follow-up care if indicated and accelerating access to expert cognitive care - delivered in weeks rather than the months-long wait times typically seen in traditional neurology care. "We're proud to partner with Neurogen on its mission to accelerate early detection and interventionist care in the fight against Alzheimer's disease, which has become all too personal for millions of Americans and their families," said Bryon Cipriani, CEO of Aranscia. "This partnership builds upon the foundational efforts of AccessDx Laboratory and 2bPrecise in helping to democratize access to personalized and precision care for all, and in ways that proactively and positively impacts the lives of the patients we help to serve." Aranscia joins Neurogen's collaborators Linus Health, which is providing the cutting-edge digital cognitive assessments for patients with memory concerns on the Neurogen Biomarking platform; Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection; and NeuroX, a venture of American TelePhysicians, to provide virtual neurology services that help guide the patient journey on its brain health care ecosystem. The platform will be widely available in mid-2025 for anyone with eligible memory and thinking concerns. Approximately 7 million Americans aged 65 and older were living with Alzheimer's dementia in 2024. It is estimated that 40% of Americans age 65+ experience memory impairment, affecting around 16 million people. Only 8% of Americans living with mild cognitive impairment receive a diagnosis, leaving 92% undiagnosed. The process of developing Alzheimer's disease is slow, with 15-20 years before the onset of Mild Cognitive Impairment (MCI). MCI precedes Alzheimer's disease by many years. About Neurogen BiomarkingNeurogen Biomarking is dedicated to supporting early detection of Alzheimer's disease and Mild Cognitive Impairment. Founded by award-winning neurologist, Dr. Rany Aburashed and guided by world-renowned brain health experts, Neurogen is on a mission to empower anyone with thinking and memory concerns with the tools, education, and motivation needed to access advanced, personalized care of patients with Alzheimer's disease – and a future with more in it. To learn more visit or follow us on LinkedIn. About Aranscia Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia's portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more information, please visit Media Contacts:Neurogen Biomarking395551@ Aranscia 395551@ View original content to download multimedia: SOURCE Aranscia Sign in to access your portfolio
